1. COMBINATORIAL SCREENING OF THE PI3K INHIBITOR COPANLISIB IN T CELL LYMPHOMAS. (June 2017) Authors: Gaudio, E.; Kwee, I.; Spriano, F.; Tarantelli, C.; Rinaldi, A.; Jourdan, T.; Berthold, M.; Arribas, A.; Stathis, A.; Rossi, D.; Liu, N.; Lange, M.; Politz, O.; Zucca, E.; Bertoni, F. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 256 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. COPANLISIB SYNERGIES WITH CONVENTIONAL AND TARGETED AGENTS INCLUDING VENETOCLAX IN PRECLINICAL MODELS OF B‐ AND T‐CELL LYMPHOMAS. (12th June 2019) Authors: Tarantelli, C.; Lange, M.; Gaudio, E.; Cascione, L.; Spriano, F.; Kwee, I.; Arribas, A.; Rinaldi, A.; Jourdan, T.; Berthold, M.; Margheriti, F.; Gritti, G.; Rossi, D.; Stathis, A.; Liu, N.; Zucca, E.; Politz, O.; Bertoni, F. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 318 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. EG‐011 IS A NOVEL SMALL MOLECULE WITH IN VITRO AND IN VIVO ANTI‐TUMOR ACTIVITY AGAINST LYMPHOMA. (12th June 2019) Authors: Gaudio, E.; Spriano, F.; Tarantelli, C.; Guala, M.; Riveiro, E.; Golino, G.; Lupia, A.; Costa, G.; Rocca, R.; Cascione, L.; Jenni, S.; Tsai, Y.; Bornhauser, B.; Alcaro, S.; Paduano, F.; Trapasso, F.; Zucca, E.; Stathis, A.; Pazzi, N.; Cavalli, F. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 513 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Improving responses to dual PI3K/BCL2 inhibition in lymphomas: results of a pharmacological screen with over 1, 400 compounds. (October 2022) Authors: Arribas, A.; Chiappa, M.; Napoli, S.; Cannas, E.; Cascione, L.; Spriano, F.; Tarantelli, C.; Rossi, D.; Zucca, E.; Alimonti, A.; Stathis, A.; Damia, G.; Broggini, M.; Bertoni, F. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. MECHANISMS OF SECONDARY RESISTANCE TO IDELALISIB IN MARGINAL ZONE LYMPHOMA. (12th June 2019) Authors: Arribas, A.; Napoli, S.; Gaudio, E.; Cascione, L.; Di Veroli, A.; Tarantelli, C.; Spriano, F.; Zucchetto, A.; Rossi, F.; Rinaldi, A.; Stathis, A.; Stussi, G.; Gattei, V.; Cruciani, G.; Zucca, E.; Rossi, D.; Bertoni, F. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 319 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Non-ATP competitive inhibition of PI3Kδ with IOA-244 shows anti-lymphoma activity. (October 2022) Authors: Tarantelli, C.; Spriano, F.; Cascione, L.; Civanelli, E.; Cannas, E.; Mensah, A.A.; Arribas, A.J.; Rinaldi, A.; Stathis, A.; Di Conza, G.; Niewola-Staszkowska, K.; Lahn, M.; Bertoni, F. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S80 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Ovarian cancer patient-derived xenografts resistant to cisplatin exhibit metabolic changes. (July 2016) Authors: Ricci, F.; Brunelli, L.; Spriano, F.; Pastorelli, R.; Damia, G. Journal: European journal of cancer Issue: Volume 61(2016)Supplement 1 Page Start: S46 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Pharmacological screening identified promising combination partners in marginal zone lymphoma models with secondary resistance to BTK and PI3K inhibitors. (October 2022) Authors: Arribas, A.; Vultaggio, S.; Andronache, A.; Robusto, M.; Fancelli, D.; Cannas, E.; Spriano, F.; Tarantelli, C.; Rossi, D.; Zucca, E.; Stathis, A.; Varasi, M.; Mercurio, C.; Bertoni, F. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S108 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. PQR309, idelalisib, duvelisib and ibrutinib lead to similar gene expression changes in activated B-cell like (ABC) diffuse large B-cell lymphoma (DLBCL). (December 2016) Authors: Arribas, A.; Rinaldi, A.; Spriano, F.; Tarantelli, C.; Gaudio, E.; Bernasconi, E.; Hillmann, P.; Kwee, I.; Stathis, A.; Fabbro, D.; Stüssi, G.; Zucca, E.; Rossi, D.; Cmiljanovic, V.; Bertoni, F. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S39 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Screening of fractions from marine sponges and other invertebrates to identify new lead compounds with anti-tumor activity in lymphoma models. (October 2020) Authors: Spriano, F.; Barreca, M.; Miguel-Gordo, M.; O'Brien, S.; Arribas, A.J.; Jennings, L.; Thomas, O.; Bertoni, F. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗